CJC-1295 (No DAC), Ipamorelin 10mg (Blend)

Overview

CJC-1295 (No DAC) is a short-acting analog of growth hormone–releasing hormone (GHRH) that stimulates the pituitary gland through the GHRH receptor to promote natural growth hormone release. Unlike the DAC version, which extends circulation time, the No DAC form has a shorter half-life, leading to a pattern of secretion that more closely mimics the body’s natural pulsatile rhythm.

Ipamorelin is a highly selective agonist of the ghrelin or growth hormone secretagogue receptor (GHSR-1a). It has been extensively studied for its ability to increase growth hormone without significantly affecting other pituitary hormones, which gives it a cleaner safety profile compared to earlier secretagogues. Research suggests it may contribute to improved muscle repair, enhanced bone health, pancreatic insulin release, and healthy digestive function.

When combined, CJC-1295 (No DAC) and Ipamorelin demonstrate synergistic effects. CJC-1295 primarily increases the frequency of growth hormone pulses, while Ipamorelin boosts their amplitude. Together, they produce a more robust and physiologically balanced growth hormone release pattern than either peptide on its own. Research-use formulations, such as 10 mg blends, are typically supplied at high purity for laboratory studies, and are not intended for therapeutic or clinical use.

CJC-1295 & Ipamorelin : Structure

CJC-1295

Type: GHRH (1–29) analog
Peptide Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
Length: 29 amino acids
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: ~3368.7 g/mol

Ipamorelin

Type: Synthetic pentapeptide, selective GH secretagogue (GHSR agonist)
Amino Acid Sequence: Aib–His–D-2-Nal–D-Phe–Lys–NH₂
Length: 5 amino acids
Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: ~711.9 g/mol

Research

Ipamorelin, the first selective growth hormone secretagogue

The discovery and pharmacological evaluation of ipamorelin, a novel and potent growth hormone (GH) secretagogue, are presented. Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that demonstrates strong GH-releasing activity both in vitro and in vivo. Developed through an extensive medicinal chemistry program, it emerged from a series of analogs that lack the central Ala-Trp dipeptide found in earlier GHRP-1 derivatives.

In primary rat pituitary cells, ipamorelin stimulated GH release with potency and efficacy comparable to GHRP-6 (EC₅₀ ≈ 1.3 ± 0.4 nmol/L, Emax ≈ 85 ± 5% vs. 2.2 ± 0.3 nmol/L and 100% for GHRP-6). Receptor profiling using antagonists confirmed that ipamorelin acts via the GHRP receptor, similar to GHRP-6. In anesthetized rats, ipamorelin induced GH secretion with an ED₅₀ of ~80 ± 42 nmol/kg and Emax of ~1545 ± 250 ng/mL, values again in line with GHRP-6 (ED₅₀ ~115 ± 36 nmol/kg, Emax ~1167 ± 120 ng/mL). Studies in conscious swine also showed nearly identical GH release between ipamorelin and GHRP-6 (ED₅₀ ≈ 2.3 ± 0.03 nmol/kg; Emax ≈ 65 ± 0.2 ng/mL vs. ED₅₀ ≈ 3.9 ± 1.4 nmol/kg; Emax ≈ 74 ± 7 ng/mL). By contrast, GHRP-2 exhibited greater potency but lower maximal response (ED₅₀ ≈ 0.6 nmol/kg; Emax ≈ 56 ± 6 ng/mL).

Importantly, ipamorelin’s specificity for GH release was confirmed in swine, as it showed no significant effects on FSH, LH, PRL, or TSH. Furthermore, while GHRP-6 and GHRP-2 increased circulating ACTH and cortisol, ipamorelin did not elevate these hormones—even at doses exceeding 200-fold above its GH-releasing threshold.

In summary, ipamorelin represents the first GHRP-receptor agonist with a selectivity for GH release comparable to GHRH, making it a highly promising candidate for future clinical development.

Combined administration of ghrelin and GHRH synergistically stimulates GH release in Holstein preweaning calves

An online ethnographic study examined how women discuss and use CJC-1295, a synthetic growth hormone analogue, within bodybuilding forums. After screening nearly one hundred forum hits, 23 discussion threads from nine sites were analyzed. Female participants reported turning to CJC-1295 for goals such as fat reduction, muscle development, youthful skin, better sleep, and injury recovery. Users often combined it with other performance and image-enhancing substances, reflecting a high level of informal pharmacological knowledge. Concerns were also raised about gender-specific differences in growth hormone activity, particularly in relation to dosing, cycling, and long-term safety. The findings highlight the need for public health strategies that address women’s self-directed use of growth hormone analogues and potential risks tied to unsupervised supplementation.

Referenced Citations

Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016 Jan 2;51(1):73-84. doi: 10.3109/10826084.2015.1082595. Epub 2016 Jan 15. PMID: 26771670.

Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.

 

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products available on this website are intended solely for in-vitro research purposes (Latin: “in glass”), meaning they are used in experiments conducted outside a living organism. These products are not medicines or drugs, have not been evaluated or approved by the U.S. Food and Drug Administration (FDA), and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Any administration to humans or animals, whether by ingestion, injection, or other means, is strictly prohibited by law.

Test

Storage Instructions:

All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.

Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.

Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you’re ready to reconstitute it with bacteriostatic water.

Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.

However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.

For further information on proper storage techniques, click the link below:

Peptide Storage